Stockscreener 앱 받기
35.89
0.69%
-0.25
시간 외 거래:
36.42
0.53
+1.48%
Harrow Inc 주식(HROW)의 최신 뉴스
What drives Harrow Inc. stock pricePhenomenal capital appreciation - Jammu Links News
Is Harrow Inc. a good long term investmentOutstanding capital appreciation - Jammu Links News
Harrow Inc. Stock Analysis and ForecastHigh-impact stock picks - Jammu Links News
What analysts say about Harrow Inc. stockAccelerated profit realization - Jammu Links News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest
Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - WV News
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView
Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus
Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan
Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World
(HROW) Trading Report - news.stocktradersdaily.com
FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World
Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance
HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target - MarketScreener
Betting on Ophthalmic Growth Amid Strong Analyst Backing: Harrow, Inc.'s Strategic Play - AInvest
Harrow: Immense Upside Potential (NASDAQ:HROW) - Seeking Alpha
Ongoing Securities Investigation into Harrow, Inc. (HROW)Contact Levi & Korsinsky - ACCESS Newswire
HROW Investor Notice: Levi & Korsinsky Investigates Harrow, Inc. for Securities Law Violations - ACCESS Newswire
William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harrow, Inc. (HROW) And Encourages Stockholders to Reach Out - ACCESS Newswire
Harrow, Inc. Fraud Investigation: A Litigation-Driven Opportunity for Shareholder Recovery - AInvest
13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey
Harrow wins new Outperform at William Blair after licensing deal for pain drug - MSN
Are Options Traders Betting on a Big Move in Harrow Stock? - TradingView
HROW to Participate in Lake Street's Virtual Meeting on June 24 - GuruFocus
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications | HROW Stock News - GuruFocus
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire
Opaleye Management Inc. Adjusts Holdings in Harrow Inc. - GuruFocus
Institutional Investors Control 46% of Harrow, Inc. (NASDAQ:HROW) and Were Rewarded Last Week After Stock Increased 4.6% - 富途牛牛
GAMMA Investing LLC Grows Stock Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
William Blair Comments on Harrow’s Q2 Earnings (NASDAQ:HROW) - Defense World
4.65%
자본화:
|
볼륨(24시간):